echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Performance analysis of multinational pharmaceutical companies in 2017: key words of innovative drugs and Chinese market

    Performance analysis of multinational pharmaceutical companies in 2017: key words of innovative drugs and Chinese market

    • Last Update: 2018-03-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [market analysis of China Pharmaceutical network] with the release of 2017 financial statements of multinational pharmaceutical companies, many people in the industry are curious about their market performance in 2017 After all, 2017 is the big year of pharmaceutical policy, and with the trend of greatly improving the competitiveness of Chinese pharmaceutical enterprises, the "report card" of multinational pharmaceutical enterprises in 2017 adds a sense of mystery From the perspective of the multinational pharmaceutical companies that have published last year's financial statements, Johnson & Johnson is the top one in global revenue, with an annual revenue of more than 70 billion US dollars for five consecutive years; Novo Nordisk accounts for 47% of the global insulin market share, accounting for 58% of the Chinese market share; Roche pharmaceutical has achieved performance growth driven by newly listed drugs However, there has been performance growth and performance decline The author has learned that Pfizer, Amgen and AstraZeneca's performance decreased by 1%, 1% and 2% respectively in 2017 Pfizer said that peri loe industry business fell by 24% and core healthcare (EH) annual revenue fell by 11%, a large part of which was due to the company's divestiture of his in February 2017, which directly affected eh revenue It's normal for the performance of enterprises to rise and fall Judging from the performance of major multinational pharmaceutical enterprises in 2017, innovative pharmaceutical business has really brought them strong assistance For example, Johnson & Johnson's immune drugs stellara (ulinumab), HIV drugs ribavirin, multiple myelomab darzalex, and imbruvica (ibudinib) all contributed to more than double-digit growth And Roche's four innovative drugs, including multiple sclerosis ocrevus, anticancer drug tecentriq, breast cancer drug Perfecta and lung cancer drug alecensa, all contributed to the growth of corporate performance In addition, Pfizer's innovative drugs, breast cancer ibrance, eliquis and xeljanz, have brought growth impetus to the enterprise, and will bring considerable profits to Pfizer in the future Novartis' innovative drugs generated $33 billion in revenue In 2017, innovative drugs became a catalyst for multinational drug companies to improve their performance, while the Chinese market provided them with more product demand At present, China is the second largest pharmaceutical consumer market in the world How can multinational pharmaceutical enterprises miss this fat? Coupled with the improvement of the speed of new drug listing and review and approval of imported new drugs in China, Teresa has become a fast approved cancer target drug in the history of CFDA, which is a good example China's market environment is becoming more and more favorable for multinational pharmaceutical enterprises Many enterprises have already begun to layout this large market Not only that, according to the analysis of the current market situation of multinational pharmaceutical enterprises in China, some experts said that, on the one hand, the strength of new drug research and development and the pharmaceutical ecological chain in China have been improved; on the other hand, CFDA's accession to ICH is also a great advantage for the development of foreign pharmaceutical enterprises in China In the future, more foreign pharmaceutical enterprises will enter the Chinese market At that time, the competition among pharmaceutical enterprises will be more fierce However, it is also analyzed by the insiders that how long the benefits of multinational pharmaceutical enterprises in China can last remains to be tested Besides seizing the opportunities as soon as possible, they also have a sense of crisis Zhao Heng, founder of latitude health, said it was not easy for multinational pharmaceutical companies to occupy more shares in the Chinese market in the context of global health insurance control For example, it is more difficult to get profits through innovative drugs into health insurance Second, many places in China have begun to implement the mechanism of payment by disease If you really want to eat the fat meat of the Chinese market, these two major challenges are that multinational pharmaceutical companies need to face and solve as soon as possible The performance of multinational pharmaceutical companies in 2017 is basically known Through analysis, it can be seen that their investment in innovative drug research and development accounts for a large proportion Despite the decline of corporate performance, their pursuit of innovative drug research and development has not been blocked In addition, the performance of multinational pharmaceutical enterprises in the Chinese market is also remarkable With the favorable environment of the Chinese pharmaceutical market and the improvement of new drug research and development capacity of domestic pharmaceutical enterprises, it is inevitable to look forward to the future trend of multinational pharmaceutical enterprises in the Chinese market.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.